title: Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.
abstract: The Oncology Gold Standard (OGS) Expert Group on renal cell carcinoma (RCC) developed the consensus statement to provide community oncologists practical guidelines on the management of advanced clear cell (cc) RCC using published evidence, practical experience of experts in real life management, and results of a nationwide survey involving 144 health-care professionals. Six broad question categories containing 33 unique questions cover major situations in the routine management of RCC. This document serves as a ready guide for the standard of care to optimize outcome. The table of "Take Home Messages" at the end is a convenient tool for busy practitioners.
authors.forename: U
authors.initials: U
authors.lastname: Batra
authors.forename: P M
authors.initials: PM
authors.lastname: Parikh
authors.forename: K
authors.initials: K
authors.lastname: Prabhash
authors.forename: H B
authors.initials: HB
authors.lastname: Tongaonkar
authors.forename: P
authors.initials: P
authors.lastname: Chibber
authors.forename: D
authors.initials: D
authors.lastname: Dabkara
authors.forename: C
authors.initials: C
authors.lastname: Deshmukh
authors.forename: N
authors.initials: N
authors.lastname: Ghadyalpatil
authors.forename: S
authors.initials: S
authors.lastname: Hingmire
authors.forename: A
authors.initials: A
authors.lastname: Joshi
authors.forename: S K
authors.initials: SK
authors.lastname: Raghunath
authors.forename: S
authors.initials: S
authors.lastname: Rajappa
authors.forename: R
authors.initials: R
authors.lastname: Rajendranath
authors.forename: S K
authors.initials: SK
authors.lastname: Rawal
authors.forename: Manisha
authors.initials: M
authors.lastname: Singh
authors.forename: R
authors.initials: R
authors.lastname: Singh
authors.forename: S P
authors.initials: SP
authors.lastname: Somashekhar
authors.forename: R
authors.initials: R
authors.lastname: Sood
keywords: Guidelines; immuno-oncology; kidney cancer; mammalian target of rapamycin inhibitor; targeted therapy; tyrosine kinase inhibitors; vascular endothelial growth factor